Esperion Therapeutics (NASDAQ:ESPR) Given Daily Coverage Optimism Rating of -0.04

Headlines about Esperion Therapeutics (NASDAQ:ESPR) have been trending somewhat negative recently, Accern Sentiment reports. The research group scores the sentiment of press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Esperion Therapeutics earned a daily sentiment score of -0.04 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 88 out of 100, meaning that recent press coverage is very likely to have an impact on the stock’s share price in the next few days.

Here are some of the headlines that may have effected Accern’s rankings:

Shares of Esperion Therapeutics (NASDAQ ESPR) traded up 0.94% on Friday, hitting $47.30. 487,052 shares of the company were exchanged. The company has a 50-day moving average price of $43.92 and a 200 day moving average price of $32.89. The firm’s market cap is $1.07 billion. Esperion Therapeutics has a 52-week low of $9.40 and a 52-week high of $50.52.

Esperion Therapeutics (NASDAQ:ESPR) last posted its quarterly earnings results on Monday, May 1st. The biopharmaceutical company reported ($1.80) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.44) by $0.36. During the same quarter in the previous year, the firm posted ($0.65) EPS. Analysts predict that Esperion Therapeutics will post ($6.69) EPS for the current fiscal year.

A number of equities analysts have commented on the stock. ValuEngine raised shares of Esperion Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. BidaskClub raised shares of Esperion Therapeutics from a “hold” rating to a “buy” rating in a research note on Sunday, June 25th. Zacks Investment Research downgraded shares of Esperion Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, May 1st. Deutsche Bank AG started coverage on shares of Esperion Therapeutics in a research note on Friday, June 23rd. They issued a “buy” rating and a $48.00 price target on the stock. Finally, Citigroup Inc. reissued a “buy” rating on shares of Esperion Therapeutics in a research note on Thursday, June 22nd. Eight investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $38.08.

ILLEGAL ACTIVITY NOTICE: “Esperion Therapeutics (NASDAQ:ESPR) Given Daily Coverage Optimism Rating of -0.04” was originally posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this piece of content on another website, it was stolen and republished in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.chaffeybreeze.com/2017/07/30/esperion-therapeutics-nasdaqespr-earns-daily-news-sentiment-rating-of-0-04-updated-updated-updated.html.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

Insider Buying and Selling by Quarter for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply